» Articles » PMID: 21324249

Barriers to Colorectal Cancer Screening: Physician and General Population Perspectives, New Mexico, 2006

Overview
Specialty Public Health
Date 2011 Feb 18
PMID 21324249
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Colorectal cancer (CRC) screening rates are low in New Mexico. We used statewide surveys of primary care physicians and the general population to characterize CRC screening practices and compare perceptions about screening barriers.

Methods: In 2006, we surveyed 714 primary care physicians in New Mexico about their CRC screening practices, beliefs, and perceptions of patient, provider, and system barriers. A 2004 state-specific CRC screening module for the Behavioral Risk Factor Surveillance System (BRFSS) survey asked 3,355 participants aged 50 years or older why they had not ever or had not recently completed a fecal occult blood test (FOBT) or lower endoscopy.

Results: The 216 physicians (30% response rate) reported offering screening to a median 80% of their average-risk patients in the past year and estimated that a median 50% were current with screening. They attributed low screening proportions mainly to patient factors (embarrassment, fear of pain, lack of insurance). However, just 51% of physician respondents used health maintenance flow sheets, and only 13% used electronic medical records to identify patients due for CRC screening. The BRFSS respondents most often reported that lack of physician discussion was responsible for not being current with screening (45% FOBT, 34% endoscopy); being asymptomatic was also often cited as an explanation for lack of screening (22% FOBT, 36% endoscopy).

Conclusion: Physicians and adults in the general population had markedly different perspectives on barriers to CRC screening. Increasing screening may require system supports to help physicians readily identify patients due for CRC testing and interventions to educate patients about the rationale for screening.

Citing Articles

Barriers and Facilitators of Colonoscopy Screening Among Latino Men in a Colorectal Cancer Screening Promotion Program.

Mojica C, Vargas N, Bradley S, Parra-Medina D Am J Mens Health. 2023; 17(3):15579883231179325.

PMID: 37287187 PMC: 10262627. DOI: 10.1177/15579883231179325.


Evaluation of Colonoscopy and Sigmoidoscopy Utilization for Colorectal Cancer Screening in Georgia, USA.

Ansa B, Hoffman Z, Lewis N, Datta B, Islam K, Johnson J Curr Oncol. 2022; 29(11):8955-8966.

PMID: 36421356 PMC: 9689714. DOI: 10.3390/curroncol29110703.


Predictors of Colorectal Cancer Screening Modality Among Newly Age-Eligible Medicaid Enrollees.

Mojica C, Lind B, Gu Y, Coronado G, Davis M Am J Prev Med. 2020; 60(1):72-79.

PMID: 33223363 PMC: 8493888. DOI: 10.1016/j.amepre.2020.08.003.


A Survey of Provider Attitudes, Beliefs, and Perceived Barriers Regarding a Centralized Direct-Mail Colorectal Cancer Screening Approach at Community Health Centers.

Thompson J, Schneider J, Rivelli J, Petrik A, Vollmer W, Fuoco M J Prim Care Community Health. 2019; 10:2150132719890950.

PMID: 31779517 PMC: 6886275. DOI: 10.1177/2150132719890950.


Colorectal Cancer Screening: Preferences, Past Behavior, and Future Intentions.

Mansfield C, Ekwueme D, Tangka F, Brown D, Smith J, Guy Jr G Patient. 2018; 11(6):599-611.

PMID: 29740804 PMC: 6226356. DOI: 10.1007/s40271-018-0308-6.


References
1.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L . Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6):1541-9. DOI: 10.1111/j.1572-0241.2008.01875.x. View

2.
Muller A, Sonnenberg A . Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med. 1995; 155(16):1741-8. DOI: 10.1001/archinte.1995.00430160065007. View

3.
Schenck A, Peacock S, Klabunde C, Lapin P, Coan J, Brown M . Trends in colorectal cancer test use in the medicare population, 1998-2005. Am J Prev Med. 2009; 37(1):1-7. DOI: 10.1016/j.amepre.2009.03.009. View

4.
Dunn A, Shridharani K, Lou W, Bernstein J, Horowitz C . Physician-patient discussions of controversial cancer screening tests. Am J Prev Med. 2001; 20(2):130-4. PMC: 4848038. DOI: 10.1016/s0749-3797(00)00288-9. View

5.
Espey D, Baum S, Jung A, Kozoll R . The New Mexico Clinical Prevention Initiative: a statewide prevention partnership. Public Health Rep. 2007; 122(3):292-301. PMC: 1847491. DOI: 10.1177/003335490712200302. View